Todos Medical Ltd. announced the appointments of Ms. Priyanka Misra as Vice President of Corporate Development and Dr. Elise Brownell as Vice President of Research & Development.  Concurrent with this announcement, the Company made key additions to its Strategic Advisory Board, with Mr. Mark Zegal joining to advise on identifying new technologies, Mr. Gurpreet Oberoi to advise on Strategic Alliances and Mr. Greg Meiselbach to advise on US Government Relations. Ms. Priyanka Misra serves as the VP of Corporate Development at Todos Medical. Her main responsibilities include designing and implementing best practices for immediate sales progression, facilitating strategic partnerships, investor relations and marketing. Priyanka has a financial background with expertise in asset management. She previously served as a senior investment analyst at family office, Geller Advisors LLC. Her responsibilities included sourcing new investment opportunities, providing investment manager due diligence, asset allocation research and portfolio construction. Dr. Elise Brownell Serves as the VP of Research & Development at Todos Medical. Her main responsibilities center around advancing the Company’s portfolio through regulatory approval. Elise’s career started at SUNY Stony Brook. She continued her interest in comparative molecular biology during her tenure at Frederick Cancer Research Facility and expanded her facility with molecular genetics while in various functions at Bayer Healthcare. Her efforts were widely recognized by promotion to Director, Project Management, where she led global cross-functional teams. Elise also became a member of the founding team of a venture-backed spin out (Aerovance, Inc), where she became head of project management. Mr. Mark Zegal is a Co-Founder of Brainstorm - Cell Therapeutics Inc. and Brain Pluristem Therapeutics Inc. Mr. Gurpreet Oberoi has been appointed to the Company’s Advisory Board to assist with Strategic Transactions. Mr. Oberoi is currently Managing Partner at Singh Global LLC in New York. Gurpreet focuses on high growth businesses with a global vision as an investor and operator. Mr. Greg Meiselbach has been appointed to the Company’s Advisory Board to assist with Government Relations. Prior to starting The Shelburne Group, Mr. Meiselbach was Director for International Affairs at the Biotechnology Innovation Organization (BIO) for five years.